Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?

Friedreichs ataxia is the commonest autosomal recessive ataxia among population of European descent. Despite the huge advances performed in the last decades, a cure still remains elusive. One of the most studied hallmarks of the disease is the increased production of oxidative stress markers in pati...

Descripción completa

Detalles Bibliográficos
Autores: R Rodriguez, Laura, Lapena, Tamara, Calap-Quintana, Pablo, Molto, Maria Dolores, Gonzalez-Cabo, Pilar, Navarro Langa, Juan Antonio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p4698
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/4698
Access Level:acceso abierto
Palabra clave:Friedreich's ataxia
clinical trials
oxidative stress
antioxidant therapies
reactive oxygen species
scavengers
antioxidant response
mitochondrial metabolism
ferroptosis
id ES_ca9692d86046975548e25da84ede32ae
oai_identifier_str oai:incliva.fundanetsuite.com:p4698
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?R Rodriguez, LauraLapena, TamaraCalap-Quintana, PabloMolto, Maria DoloresGonzalez-Cabo, PilarNavarro Langa, Juan AntonioFriedreich's ataxiaclinical trialsoxidative stressantioxidant therapiesreactive oxygen speciesscavengersantioxidant responsemitochondrial metabolismferroptosisFriedreichs ataxia is the commonest autosomal recessive ataxia among population of European descent. Despite the huge advances performed in the last decades, a cure still remains elusive. One of the most studied hallmarks of the disease is the increased production of oxidative stress markers in patients and models. This feature has been the motivation to develop treatments that aim to counteract such boost of free radicals and to enhance the production of antioxidant defenses. In this work, we present and critically review those "antioxidant" drugs that went beyond the diseases models and were approved for its application in clinical trials. The evaluation of these trials highlights some crucial aspects of the FRDA research. On the one hand, the analysis contributes to elucidate whether oxidative stress plays a central role or whether it is only an epiphenomenon. On the other hand, it comments on some limitations in the current trials that complicate the analysis and interpretation of their outcome. We also include some suggestions that will be interesting to implement in future studies and clinical trials.MDPI2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/4698AntioxidantsISSN: 20763921reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p46982026-06-07T16:35:31Z
dc.title.none.fl_str_mv Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
title Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
spellingShingle Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
R Rodriguez, Laura
Friedreich's ataxia
clinical trials
oxidative stress
antioxidant therapies
reactive oxygen species
scavengers
antioxidant response
mitochondrial metabolism
ferroptosis
title_short Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
title_full Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
title_fullStr Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
title_full_unstemmed Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
title_sort Antioxidant Therapies and Oxidative Stress in Friedreich's Ataxia: The Right Path or Just a Diversion?
dc.creator.none.fl_str_mv R Rodriguez, Laura
Lapena, Tamara
Calap-Quintana, Pablo
Molto, Maria Dolores
Gonzalez-Cabo, Pilar
Navarro Langa, Juan Antonio
author R Rodriguez, Laura
author_facet R Rodriguez, Laura
Lapena, Tamara
Calap-Quintana, Pablo
Molto, Maria Dolores
Gonzalez-Cabo, Pilar
Navarro Langa, Juan Antonio
author_role author
author2 Lapena, Tamara
Calap-Quintana, Pablo
Molto, Maria Dolores
Gonzalez-Cabo, Pilar
Navarro Langa, Juan Antonio
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Friedreich's ataxia
clinical trials
oxidative stress
antioxidant therapies
reactive oxygen species
scavengers
antioxidant response
mitochondrial metabolism
ferroptosis
topic Friedreich's ataxia
clinical trials
oxidative stress
antioxidant therapies
reactive oxygen species
scavengers
antioxidant response
mitochondrial metabolism
ferroptosis
description Friedreichs ataxia is the commonest autosomal recessive ataxia among population of European descent. Despite the huge advances performed in the last decades, a cure still remains elusive. One of the most studied hallmarks of the disease is the increased production of oxidative stress markers in patients and models. This feature has been the motivation to develop treatments that aim to counteract such boost of free radicals and to enhance the production of antioxidant defenses. In this work, we present and critically review those "antioxidant" drugs that went beyond the diseases models and were approved for its application in clinical trials. The evaluation of these trials highlights some crucial aspects of the FRDA research. On the one hand, the analysis contributes to elucidate whether oxidative stress plays a central role or whether it is only an epiphenomenon. On the other hand, it comments on some limitations in the current trials that complicate the analysis and interpretation of their outcome. We also include some suggestions that will be interesting to implement in future studies and clinical trials.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/4698
url https://incliva.portalinvestigacion.com/publicaciones/4698
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Antioxidants
ISSN: 20763921
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419493158027264
score 15,811543

Similares en LA Referencia